A meta-analysis demonstrated the superiority of Bruton tyrosine kinase inhibitors (BKTi) in the overall survival of patients with chronic lymphocytic leukemia compared with other therapies. 15 ...

Novel targeted therapies for R/R CLL, including venetoclax plus rituximab, acalabrutinib, and zanubrutinib, have favorable safety profiles. Bendamustine plus rituximab showed a lower risk of severe ...

In just over a year since its US Food and Drug Administration (FDA) approval, pirtobrutinib (Jayprica) has become a standard therapy for patients with chronic lymphocytic leukemia (CLL) who have ...

BGB-16673 is an investigational oral BTK-targeted chimeric degradation activation compound. The Food and Drug Administration (FDA) has granted Fast Track designation to BGB-16673 for the treatment of ...

Editor’s note: This is an automatically generated transcript. Please notify editor@healio.com if there are concerns regarding accuracy of the transcription. Relapsed/refractory CLL, I do kind of ...

Jaypirca showed higher overall response rates than Imbruvica in both treatment-naive and relapsed/refractory CLL/SLL populations. Progression-free survival trends favored Jaypirca, especially in ...

Share on Facebook. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window SAN DIEGO -- Single-agent epcoritamab (Epkinly) achieved ...

Current and emerging treatments for relapsed or refractory CLL show promise, with outcomes expected to improve beyond current data. Treatment responses in CLL can last for years, especially in ...

At a median duration of follow-up of 6.6 months, treatment with pirtobrutinib reduced the risk of progression or death by 42%. The Food and Drug Administration (FDA) has approved Jaypirca ® ...

A fixed-duration, three-drug regimen for chronic lymphocytic leukemia (CLL) achieved deep and durable remissions lasting for up to 7 years, according to updated results from a prospective study.

ORLANDO, Florida — Another phase 3 trial has shown efficacy for idelalisib (Zydelig, Gilead Sciences, Inc) in relapsed or refractory chronic lymphocytic leukemia (CLL). The novel drug was approved ...

Preliminary analyses from the EPCORE® CLL-1 trial demonstrates overall response rate (ORR) of 61 percent and complete response (CR) rate of 39 percent in heavily pretreated patients with relapsed or ...